Nanoparticles as potential clinical therapeutic agents in Alzheimer's disease: focus on selenium nanoparticles


NAZIROĞLU M. , MUHAMAD S., Pecze L.

EXPERT REVIEW OF CLINICAL PHARMACOLOGY, vol.10, no.7, pp.773-782, 2017 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 10 Issue: 7
  • Publication Date: 2017
  • Doi Number: 10.1080/17512433.2017.1324781
  • Title of Journal : EXPERT REVIEW OF CLINICAL PHARMACOLOGY
  • Page Numbers: pp.773-782

Abstract

Introduction: In etiology of Alzheimer's disease (AD), involvement of amyloid (A) plaque accumulation and oxidative stress in the brain have important roles. Several nanoparticles such as titanium dioxide, silica dioxide, silver and zinc oxide have been experimentally using for treatment of neurological disease. In the last decade, there has been a great interest on combination of antioxidant bioactive compounds such as selenium (Se) and flavonoids with the oxidant nanoparticles in AD. We evaluated the most current data available on the physiological effects of oxidant and antioxidant nanoparticles.